Vera Therapeutics, Inc. VERA
- TRUTAKNA — IgA Nephropathy Approved
- TRUTAKNA — Primary Membranous Nephropathy Phase 2
- TRUTAKNA — Focal Segmental Glomerulosclerosis Phase 2
- TRUTAKNA — Minimal Change Disease Phase 2
- VT-109 Preclinical
BAFF (3 companies · 10 programs)
Companies with an active program directed at BAFF.
Zura Bio Ltd ZURA
- tibulizumab — Hidradenitis Suppurativa Phase 2
- tibulizumab — Diffuse Cutaneous Systemic Sclerosis Phase 2
- tibulizumab — Polymyalgia Rheumatica
Vor Biopharma Inc. VOR
- telitacicept — Generalized Myasthenia Gravis Phase 3
- telitacicept — Sjögren's Disease Phase 3